Driehaus Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Driehaus Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30,000	Closed	-$456K	–	352
2022 Q3	$456K	Buy	+30,000	New	+$497K	0.01%	317
2017 Q4	–	Sell	-3,971	Closed	-$892K	–	532
2017 Q3	$892K	Sell	3,971 -4,258	-52%	-$1.05M	0.03%	333
2017 Q2	$2.25M	Buy	8,229 +2,835	+53%	+$768K	0.08%	242
2017 Q1	$1.3M	Buy	5,394 +1,403	+35%	+$321K	0.04%	328
2016 Q4	$828K	Sell	3,991 -2,016	-34%	-$479K	0.03%	373
2016 Q3	$1.64M	Buy	+6,007	New	+$1.33M	0.06%	298
2016 Q1	–	Sell	-15,881	Closed	-$3.41M	–	546
2015 Q4	$3.41M	Buy	+15,881	New	+$2.9M	0.12%	205
2015 Q3	–	Sell	-6,661	Closed	-$1.72M	–	542
2015 Q2	$1.72M	Buy	+6,661	New	+$1.59M	0.06%	357

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Driehaus Capital Management's AXDX Position: Q4 2022 in Review

Driehaus Capital Management sold out of Accelerate Diagnostics (AXDX) in Q4 2022, closing a stake of 30,000 shares — an estimated $456K sold.

Driehaus Capital Management first reported a position in AXDX in Q2 2015 and held it in 8 quarters. The position peaked at $3.41M in Q4 2015. 73 funds tracked by Wall St. Rank hold AXDX as of Q4 2022.

Driehaus Capital Management reported no remaining Accelerate Diagnostics position as of Q4 2022 after selling out during the quarter.
Driehaus Capital Management sold 30,000 Accelerate Diagnostics shares in Q4 2022, an estimated $456K.
Driehaus Capital Management first reported a position in Accelerate Diagnostics in Q2 2015 and held it in 8 quarters.
Driehaus Capital Management's Accelerate Diagnostics position peaked at $3.41M in Q4 2015.
73 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2022.

Based on Driehaus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.